Clinical trial
Combination Chemotherapy as First-Line Therapy in Treating Patients With…
NCT00112658 · UNICANCER, Other · Completed
Key facts
| NCT number | NCT00112658 |
|---|---|
| Title | Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer |
| Official title | Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients |
| Lead sponsor | UNICANCER, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, leucovorin calcium, oxaliplatin |
| Enrollment | 342 |
| Start date | Nov 1, 2004 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 30, 2010 |
| First posted | Jun 3, 2005 |
| Last update posted | Mar 8, 2021 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: